Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Barinthus Biotherapeutics (BRNS) Enterprise Value (2020 - 2025)

Barinthus Biotherapeutics' Enterprise Value history spans 6 years, with the latest figure at -$1.3 million for Q4 2025.

  • For Q4 2025, Enterprise Value rose 19.61% year-over-year to -$1.3 million; the TTM value through Dec 2025 reached -$1.3 million, up 19.61%, while the annual FY2025 figure was -$1.3 million, 19.61% up from the prior year.
  • Enterprise Value reached -$1.3 million in Q4 2025 per BRNS's latest filing, up from -$75.6 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of $19.6 million in Q1 2021 to a low of -$243.1 million in Q2 2021.
  • Average Enterprise Value over 5 years is -$137.1 million, with a median of -$151.0 million recorded in 2023.
  • Peak YoY movement for Enterprise Value: tumbled 54733.5% in 2021, then surged 98.85% in 2024.
  • A 5-year view of Enterprise Value shows it stood at -$213.6 million in 2021, then rose by 9.15% to -$194.1 million in 2022, then grew by 26.9% to -$141.9 million in 2023, then soared by 98.85% to -$1.6 million in 2024, then increased by 19.61% to -$1.3 million in 2025.
  • Per Business Quant, the three most recent readings for BRNS's Enterprise Value are -$1.3 million (Q4 2025), -$75.6 million (Q3 2025), and -$87.7 million (Q2 2025).